Self Timothy H, Twilla Jennifer D, Rogers Maegan L, Rumbak Mark J
University of Tennessee Health Science Center, Methodist University Hospital, Memphis, Tennessee 38163, USA.
J Asthma. 2009 Dec;46(10):974-9. doi: 10.3109/02770900903274483.
National and International Guidelines concur that inhaled corticosteroids (ICS) are the preferred long-term maintenance drug therapy for mild persistent asthma for all ages. For moderate and severe persistent asthma, ICS are essential to optimal management, often concurrent with other key therapies. Despite strong evidence and consensus guidelines, ICS are still underused. While some patients who are treated in the emergency department (ED) have intermittent asthma, most have persistent asthma and need ICS for optimum outcomes. Failure to initiate ICS at this critical juncture often results in subsequent lack of ICS therapy. Along with a short course of oral corticosteroids, ICS should be initiated before discharge from the ED in patients with persistent asthma. Although the NIH/NAEPP Expert Panel Report 3 suggests considering the prescription of ICS on discharge from the ED, The Global Initiative for Asthma (GINA) 2008 guidelines recommend initiation or continuation of ICS before patients are discharged from the ED. The initiation of ICS therapy by ED physicians is also encouraged in the emergency medicine literature over the past decade. Misdiagnosis of intermittent asthma is common; therefore, ICS therapy should be considered for ED patients with this diagnosis with reassessment in follow-up office visits. To help ensure adherence to ICS therapy, patient education regarding both airway inflammation (show airway models/colored pictures) and the strong evidence of efficacy is vital. Teaching ICS inhaler technique, environmental control, and giving a written action plan are essential. Lack of initiation of ICS with appropriate patient education before discharge from the ED in patients with persistent asthma is common but unfortunately associated with continued poor patient outcomes.
国内和国际指南均一致认为,吸入性糖皮质激素(ICS)是各年龄段轻度持续性哮喘首选的长期维持药物治疗。对于中度和重度持续性哮喘,ICS是优化管理的关键,通常与其他关键疗法联合使用。尽管有充分的证据和共识性指南,但ICS的使用仍不充分。虽然在急诊科(ED)接受治疗的一些患者患有间歇性哮喘,但大多数患者患有持续性哮喘,需要使用ICS以获得最佳疗效。在这个关键时刻未能启动ICS治疗往往会导致随后缺乏ICS治疗。对于持续性哮喘患者,除了短期口服糖皮质激素外,应在出院前启动ICS治疗。尽管美国国立卫生研究院/美国国家心肺血液研究所专家小组报告3建议考虑在急诊科出院时开具ICS处方,但《全球哮喘防治创议》(GINA)2008指南建议在患者从急诊科出院前启动或继续使用ICS。在过去十年的急诊医学文献中也鼓励急诊科医生启动ICS治疗。间歇性哮喘的误诊很常见;因此,对于诊断为此病的急诊科患者应考虑使用ICS治疗,并在后续门诊复诊时进行重新评估。为帮助确保患者坚持ICS治疗,关于气道炎症(展示气道模型/彩色图片)和疗效有力证据的患者教育至关重要。教授ICS吸入技术、环境控制并提供书面行动计划必不可少。持续性哮喘患者在急诊科出院前未启动ICS并进行适当的患者教育很常见,但不幸的是这与患者持续的不良预后相关。